“The sponsor has not conducted carcinogenicity studies citing ICH M3 (R2) since the product is intended for short-term use.”
✓ VerifiedFDA pharmacology/toxicology review, p. 63Source ↗
Instead of carcinogenicity
Not stated in public reviews
Not reported in the public reviews. Reviewers summarise selectively, so this usually means it wasn't discussed publicly, not that it wasn't studied.
Instead of genotoxicity
Not stated in public reviews
Not reported in the public reviews. Reviewers summarise selectively, so this usually means it wasn't discussed publicly, not that it wasn't studied.
DRG histopathology
Not stated in public reviews
Not reported in the public reviews. Reviewers summarise selectively, so this usually means it wasn't discussed publicly, not that it wasn't studied.
Reproductive & developmental
Rat: low pup viability at 50-100 mg/kg/day and lower male fetal weight at 100 mg/kg/day; no malformations
“Viability was low for rat pups in the 50 or 100 mg/kg/day groups, and body weight of male fetuses were decreased in the 100 mg/kg/day group, but there were no malformations.”
✓ VerifiedFDA pharmacology/toxicology review, p. 23Source ↗
Safety pharmacology
hERG IC50 >300 µM for landiolol (~5-fold Cmax at MRHD) and >1,000 µM for metabolites M-1 and M-2
“IC50 of >300 µM (>21µM free) was predicted for LAN, representing 5-fold the Cmax at MRHD. IC50 of >1,000 µM was predicted for the metabolites M-1 and M-2.”
✓ VerifiedFDA pharmacology/toxicology review, p. 18Source ↗
Genotox: Ames
Negative
“Landiolol was not genotoxic when tested in a battery of assays (Ames, in vitro mouse lymphoma TK +/- , and in vivo micronucleus test in rats).”
“IC50 of >300 µM (>21µM free) was predicted for LAN, representing 5-fold the Cmax at MRHD. IC50 of >1,000 µM was predicted for the metabolites M-1 and M-2.”
✓ VerifiedFDA pharmacology/toxicology review, p. 18Source ↗
Not genotoxic overall: Ames negative; in vitro chromosome aberration positive without (not with) metabolic activation; rat micronucleus and comet negative